0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Commentary |

Should Sisyphus Have Taken Melatonin?

William M. Glazer, MD; Scott W. Woods, MD; Don Goff, MD
Arch Gen Psychiatry. 2001;58(11):1054-1055. doi:10.1001/archpsyc.58.11.1054.
Text Size: A A A
Published online

Extract

IS MELATONIN a new inroad into the treatment and understanding of the pathophysiologic characteristics of tardive dyskinesia (TD), or is it just another boulder in the Sisyphean history of treatments for iatrogenic conditions? In this issue of the ARCHIVES, Shamir et al1 report the effectiveness of a 6-week trial of melatonin, 10 mg/d, relative to placebo in 22 patients. The authors postulate, among many possible mechanisms,2 that melatonin asserts a modulatory effect on dopamine release or a neuroprotective, antioxidative action on brain dopaminergic functioning. What is the relevance of this finding to research strategies and treatment approaches in patients? Certainly TD has been a driving force behind the effort to develop better antipsychotic agents. The estimated 68% risk of TD after 20 to 25 years of exposure to the older "typical" antipsychotic drugs is a public health problem.3 Unquestionably, we need ways to treat and prevent this iatrogenic condition.

Topics

melatonin

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();